Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 180 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Short Stature Clear all
Terminated No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Short Stature, Growth Disorder, Syndromic Growth Disorder, Tall Stature
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
3 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions
Lonapegsomatropin, Placebo, Somatropin
Drug · Other
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
23 Years to 80 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced May 22, 2026, 1:30 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Pseudohypoparathyroidism Type 1A, Albright Hereditary Osteodystrophy, Pseudopseudohypoparathyroidism
Interventions
Neurocognitive and psychosocial testing
Behavioral
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
2 Months to 89 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2030
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced May 22, 2026, 1:30 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Mucopolysaccharidosis IV Type A, Morquio A Syndrome, MPS IVA
Interventions
Imaging, gait analysis, growth, joint test, hearing test, questionnaire, etc.
Diagnostic Test
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 22, 2026, 1:30 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Gulf War Syndrome, Adult Growth Hormone Deficiency
Interventions
Recombinant human growth hormone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumors
Interventions
Genz-644282 (28-day dosing schedule), Genz-644282 (21-day dosing schedule)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced May 22, 2026, 1:30 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Achondroplasia
Interventions
Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
15 Months and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
9
States / cities
Oakland, California • Torrance, California • Wilmington, Delaware + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg, Infigratinib 0.128 mg/kg, Infigratinib 0.25 mg/kg
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
3 Years to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Oakland, California • Wilmington, Delaware • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced May 22, 2026, 1:30 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Achondroplasia, Dwarfism
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 22, 2026, 1:30 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Achondroplasia
Interventions
Not listed
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
0 Months to 18 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Oakland, California • San Francisco, California • Statesville, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Short Stature, Constitutional Delay of Growth and Development, Dwarfism, Pituitary
Interventions
Growth Hormone Therapy
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 10 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Growth Hormone Deficiency, Traumatic Brain Injury
Interventions
Recombinant human growth hormone
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
2
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced May 22, 2026, 1:30 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Growth Hormone
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Adult Growth Hormone Deficiency
Interventions
somavaratan
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
23 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Escondido, California • Laguna Hills, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
LUM-201, rhGH Norditropin® pen (34 µg/kg)
Drug
Lead sponsor
Lumos Pharma
Industry
Eligibility
3 Years to 12 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
27
States / cities
Sacramento, California • San Diego, California • Greenwood Village, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Constitutional Growth Delay, Nutrition Disorders, Growth Disorders
Interventions
Pediasure, GH
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
7 Years to 10 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Macimorelin, Arginine, Clonidine
Drug · Diagnostic Test
Lead sponsor
AEterna Zentaris
Industry
Eligibility
2 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Greenwood Village, Colorado • St. Petersburg, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years to 14 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Oakland, California • Torrance, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced May 22, 2026, 1:30 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Turner Syndrome, Idiopathic Short Stature
Interventions
somatropin (rDNA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 14 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2009 · Synced May 22, 2026, 1:30 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
DNA Repair Disorder, Cockayne Syndrome, Xeroderma Pigmentosum, Trichothiodystrophy
Interventions
Interval History, Physical Examination, ECAB Assessment, Gait Assessment, Specimen Sample Collection
Other
Lead sponsor
University of Minnesota
Other
Eligibility
6 Months and older
Enrollment
40 participants
Timeline
2022 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced May 22, 2026, 1:30 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Healthy, Growth Hormone Deficiency
Interventions
growth hormone and lirglutide, growth hormone, liraglutide, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced May 22, 2026, 1:30 AM EDT
Not listed Phase 3 Interventional
View directory record Official record
Conditions
Growth Hormone Deficiency (GHD)
Interventions
growth hormone (somatropin)
Drug
Lead sponsor
LG Life Sciences
Industry
Eligibility
3 Years to 11 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2010 · Synced May 22, 2026, 1:30 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Growth Hormone Deficiency, Dwarfism
Interventions
Dextromethorphan and Caffeine
Drug
Lead sponsor
University of Louisville
Other
Eligibility
4 Years to 14 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
4
States / cities
San Diego, California • Louisville, Kentucky • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced May 22, 2026, 1:30 AM EDT